Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
SHANGHAI, July 11, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totalingUS$3.2 billion, including USD Fund VIII atUS$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversub...
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research
TIANJIN, China, April 25, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: , HKEX: 06185) today announced its new brand identity, which is intended to represent the Company's continuous dedication to life sciences research and its commitment to protecting the glo...
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
SHANGHAI, April 13, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, andDuane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list. Since ...
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China
TIANJIN, April 4, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration ofChina ("NMPA") granted approval for the clinical trial application of its COVID-19 mRNA vaccine inChina. Pr...
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia
TIANJIN, China, March 22, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Ministry of Health Malaysia ("MO...
Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant
TIANJIN, China, March 14, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that medRxiv, a preprint platform for preliminary biomedical research, published an academic paper1 on the efficacy of CanSinoBIO's Recombinant COVID-19 Vaccine ("Ad5-n...
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China
TIANJIN, China, Feb. 21, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Joint Prevention and Control Mechanism ...
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
TIANJIN, China, Jan. 9, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration ofChina ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) ("MCV4", trade name: Menhycia™), ma...
Convidecia™ Phase III Results Published in The Lancet
* 96.0% effective against severe disease 14 days post-vaccination for population aged 18 and above. * Single-dose vaccine received approvals in at least 10 markets including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia. TIANJIN, China, Dec. ...
CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™
* A major step for introducing Convidecia™ to more countries and people in need for protection * Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile * Provides timely clinical protection for adults aged 18 and above, including those over 60 TIANJIN, China, May 24, 2021 /P...
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile
* Marks vaccine's first approval in South America, following Mexico, Pakistan, China and Hungary * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TI...
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary
* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...
CanSinoBIO's Successful Listing on STAR Market Makes it the Initial Dual Listing Vaccine Company
SHANGHAI, Aug. 13, 2020 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SHSE: 688185, HKEX:06185) announced today that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company. CanSinoB...
